ReviewEuropean cardiology2019
AF in Cancer Patients: A Different Need for Anticoagulation?
Review in European cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 0 citations in OpenAlex.
- Comparison of Direct Oral Anticoagulants and Low-Molecular-Weight Heparins in Cancer Patients with Nonvalvular Atrial Fibrillation: Insights from a Single-Center Experience.Anatolian journal of cardiology · 2026Article
- Low-molecular-weight heparins in atrial fibrillation: clinical scenarios, limitations, and future perspectives.Frontiers in pharmacology · 2026Review
- Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies.Journal of thrombosis and thrombolysis · 2022Article
- Breast Cancer and Atrial Fibrillation.Journal of clinical medicine · 2022Review
- Capecitabine and Warfarin Interaction: A Case Report With Review of Literature and Management Options.Frontiers in cardiovascular medicine · 2021Article
- Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter.JACC. CardioOncology · 2020Article
- Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors.Current treatment options in oncology · 2020Review
- Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation.Anatolian journal of cardiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer and cancer therapies might be a risk factor for developing Atrial Fibrillation (AF). It remains unclear if one is the cause or consequence of the other, or if they simply coexist. An unpredictable response to anticoagulation can be expected, as a result of the lack of information in oncology patients. The balance between thromboembolic and bleeding risks of AF in these patients is particularly challenging. Little is known about whether embolic and bleeding risk scores used for the general population can be applied in oncologic patients. Cardiology involvement in the management of these patients seems to be associated with favourable AF-related outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.